Novo Nordisk A/S
NOVO-B
Rank in Stocks
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$39.74
Market Cap
$175.38B
Change (1 day)
1.28%
Change (1 year)
-25.58%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)
Category
Healthcare
Revenue for Novo Nordisk A/S (NOVO-B)
Revenue in Dec 2025 TTM: $48.55B
According to Novo Nordisk A/S latest financial reports the company's current revenue (TTM) is $48.55B. In 2024 the company made a revenue of $40.52B an increase over the revenue in the year 2023 that was $34.39B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novo Nordisk A/S from 2001 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $48.55B | 0.00% |
| 2025 | $48.55B | 19.82% |
| 2024 | $40.52B | 17.82% |
| 2023 | $34.39B | 35.02% |
| 2022 | $25.47B | 18.29% |
| 2021 | $21.53B | 3.33% |
| 2020 | $20.84B | 13.79% |
| 2019 | $18.31B | 6.63% |
| 2018 | $17.17B | -4.59% |
| 2017 | $18.00B | 13.46% |
| 2016 | $15.86B | 0.88% |
| 2015 | $15.73B | 8.89% |
| 2014 | $14.44B | -6.28% |
| 2013 | $15.41B | 11.69% |
| 2012 | $13.80B | 19.42% |
| 2011 | $11.55B | 6.01% |
| 2010 | $10.90B | 10.52% |
| 2009 | $9.86B | 15.53% |
| 2008 | $8.54B | 3.65% |
| 2007 | $8.24B | 20.44% |
| 2006 | $6.84B | 28.15% |
| 2005 | $5.34B | -0.14% |
| 2004 | $5.34B | 18.51% |
| 2003 | $4.51B | 27.01% |
| 2002 | $3.55B | 25.45% |
| 2001 | $2.83B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $79.67B | 64.10% |
US
|
|
| $99.34B | 104.61% |
US
|
|
| $64.39B | 32.62% |
US
|
|
| $66.40B | 36.77% |
US
|
|
| $77.52B | 59.67% |
CH
|
